Colorado 2022 Regular Session

Colorado Senate Bill SB027

Introduced
1/12/22  
Refer
1/12/22  
Report Pass
2/9/22  
Refer
2/9/22  
Engrossed
2/16/22  
Refer
2/16/22  
Report Pass
5/2/22  
Refer
5/2/22  
Enrolled
5/9/22  
Engrossed
5/18/22  
Engrossed
5/18/22  
Enrolled
5/18/22  

Caption

Prescription Drug Monitoring Program

Impact

The implementation of SB 027 will principally affect healthcare providers, specifically prescribers and pharmacists. By mandating that all licensed practitioners and pharmacists maintain user accounts within the monitoring program, the legislation aims to ensure that drug prescription practices are closely tracked and evaluated. This change is expected to improve compliance with existing regulations, ultimately leading to better management of prescription medications and the mitigation of abuse and dependency. Additionally, the establishment of a task force to oversee program functionalities indicates a commitment to ongoing evaluation and improvement in reducing prescription drug misuse.

Summary

Senate Bill 027, also known as the Prescription Drug Monitoring Program, seeks to modify existing state laws based on recommendations from a March 2021 audit report issued by the Office of the State Auditor. The bill emphasizes more stringent regulation over prescription practices related to opioids and benzodiazepines, requiring prescribers to adhere to specific guidelines before authorizing second fills of these medications. The proposal represents a broader effort to tackle prescription drug misuse in Colorado, a concern that has been amplified amid rising addiction rates and overdose incidents.

Sentiment

Discussions surrounding SB 027 have generally leaned toward a supportive sentiment, particularly among health advocates and providers concerned about the public health implications of prescription drug misuse. Proponents argue that these regulatory measures are necessary for ensuring patient safety and preventing addiction. However, some concerns have been raised about potential hurdles that healthcare providers might face in adhering to these new requirements, indicating a degree of apprehension about the operational impacts on prescribers and pharmacists.

Contention

One notable point of contention relates to the balance between enhancing enforcement of drug laws while ensuring that the monitoring program serves as an effective healthcare tool. Critics worry that overly stringent regulations could impede the ability of healthcare providers to prescribe necessary medications responsibly and effectively. The Bill's focus on utilizing audit-driven revisions to existing statutes also raises questions about the adequacy of stakeholder engagement in the development process, which may impact its reception among the medical community.

Companion Bills

No companion bills found.

Previously Filed As

CO HB1438

Implement Prescription Drug Affordability Programs

CO SB047

Prevention of Substance Use Disorders

CO HB1115

Prescription Drug Label Accessibility

CO SB061

Creating a Drug Donation Program

CO SB077

Prescription Drug Manufacturer Requirements

CO SB060

Prescription Drug Affordability Board Exempt Orphan Drugs

CO SB168

Remote Monitoring Services for Medicaid Members

CO SB203

Prescription Drug Board Consider Rare Disease Advisory Council

CO HB1045

Treatment for Substance Use Disorders

CO HB1171

Naturopathic Doctor Formulary

Similar Bills

No similar bills found.